Akero Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKRO and other ETFs, options, and stocks.About AKRO
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
AKRO Key Statistics
Stock Snapshot
Akero Therapeutics(AKRO) stock is priced at $54.20, giving the company a market capitalization of 4.47B. It carries a P/E multiple of -14.46.
On 2025-11-14, Akero Therapeutics(AKRO) stock traded between a low of $54.16 and a high of $54.31. Shares are currently priced at $54.20, which is +0.1% above the low and -0.2% below the high.
Akero Therapeutics(AKRO) shares are trading with a volume of 1.83M, against a daily average of 1.64M.
In the last year, Akero Therapeutics(AKRO) shares hit a 52-week high of $58.40 and a 52-week low of $21.34.
In the last year, Akero Therapeutics(AKRO) shares hit a 52-week high of $58.40 and a 52-week low of $21.34.
AKRO News
Akero Therapeutics (AKRO) announced new findings from the SYMMETRY and HARMONY Phase 2b trials of efruxifermin in patients with compensated cirrhosis due to met...